Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
⏸️ Investing
Is the Mesoblast limited share price good value?
⏸️ Investing
7 shares you need to watch on Thursday
⏸️ Investing
Why these 4 ASX shares have sunk like stones today
⏸️ Investing
ALL ORDINARIES finishes lower Thursday: 8 shares you missed
⏸️ Investing
S&P/ASX 200 finishes flat Friday: 11 shares you missed
⏸️ Investing
Why these 3 shares just made new 52-week highs
⏸️ Investing
S&P/ASX 200 finishes higher Friday: 9 shares you missed
⏸️ Investing
S&P/ASX 200 wrap: bad Thursday before Good Friday
⏸️ Investing
Why these 4 shares are getting crushed today
⏸️ Investing
Scaling new heights: Is it too late to buy Mesoblast, Gentrack, and Corporate Travel Management?
⏸️ Investing
BHP in the spotlight on Tuesday: 9 shares you need to watch today
⏸️ Investing
Why these 4 ASX shares have started the week with a BANG
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
